Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally.
High growth potential with adequate balance sheet.
Share Price & News
How has Ardelyx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARDX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ARDX exceeded the US Biotechs industry which returned 28.5% over the past year.
Return vs Market: ARDX exceeded the US Market which returned 6.7% over the past year.
Price Volatility Vs. Market
How volatile is Ardelyx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDoes Ardelyx (NASDAQ:ARDX) Have A Healthy Balance Sheet?
4 weeks ago | Simply Wall StHave Ardelyx, Inc. (NASDAQ:ARDX) Insiders Been Selling Their Stock?
1 month ago | Simply Wall StCould The Ardelyx, Inc. (NASDAQ:ARDX) Ownership Structure Tell Us Something Useful?
Is Ardelyx undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ARDX ($6.42) is trading below our estimate of fair value ($55.77)
Significantly Below Fair Value: ARDX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ARDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ARDX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARDX's PB Ratio (3.4x) is in line with the US Biotechs industry average.
How is Ardelyx forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: ARDX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ARDX's is expected to become profitable in the next 3 years.
Revenue vs Market: ARDX's revenue (67.1% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: ARDX's revenue (67.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARDX's Return on Equity is forecast to be high in 3 years time
How has Ardelyx performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARDX is currently unprofitable.
Growing Profit Margin: ARDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARDX is unprofitable, and losses have increased over the past 5 years at a rate of -19.2% per year.
Accelerating Growth: Unable to compare ARDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: ARDX has a negative Return on Equity (-54.35%), as it is currently unprofitable.
How is Ardelyx's financial position?
Financial Position Analysis
Short Term Liabilities: ARDX's short term assets ($228.6M) exceed its short term liabilities ($23.4M).
Long Term Liabilities: ARDX's short term assets ($228.6M) exceed its long term liabilities ($44.1M).
Debt to Equity History and Analysis
Debt Level: ARDX's debt to equity ratio (29.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ARDX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARDX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Ardelyx current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Raab (55yo)
Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019. Mr. Raab was a V ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD1.73M) is about average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
|Chief Legal & Administrative Officer and Secretary||0.50yr||US$791.41k||0.12% $659.2k|
|Chief Development Officer||5.5yrs||US$812.66k||0.17% $970.7k|
|Chief Accounting & Principal Financial Officer||0.083yr||no data||0.0034% $19.3k|
|Chief Scientific Officer||0.42yr||no data||0.051% $292.6k|
|Manager of Corporate Communications & Investor Relations||no data||no data||no data|
|Chief Regulatory Affairs & Quality Assurance Officer||no data||no data||0.017% $98.9k|
|Senior Director Market Development||no data||no data||no data|
|Senior Director of Market Development||no data||no data||no data|
|Chief Commercial Officer||0.17yr||no data||no data|
|Vice President of Payer Access||no data||no data||no data|
Experienced Management: ARDX's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
|Independent Chairman||6.33yrs||US$184.49k||0.28% $1.6m|
|Independent Director||6.08yrs||US$144.49k||0.011% $64.2k|
|Independent Director||4.75yrs||US$144.49k||0.067% $383.0k|
|Independent Director||2.33yrs||US$141.99k||0.040% $228.6k|
|Independent Director||6.33yrs||US$161.99k||0.087% $498.3k|
|Independent Director||1.33yrs||US$230.51k||no data|
|Independent Director||4.08yrs||US$141.99k||no data|
|Independent Director||0.33yr||no data||0.0069% $39.5k|
Experienced Board: ARDX's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ARDX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.3%.
Ardelyx, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ardelyx, Inc.
- Ticker: ARDX
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$571.744m
- Shares outstanding: 89.06m
- Website: https://www.ardelyx.com
Number of Employees
- Ardelyx, Inc.
- 34175 Ardenwood Boulevard
- Suite 200
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ARDX||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2014|
|41X||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2014|
Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company’s lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/13 07:27|
|End of Day Share Price||2020/07/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.